Rhône-Poulenc Rorer Inc. regulatory update

The FDA approved Rilutek (riluzole) to treat amyotrophic lateral sclerosis. Rilutek will be available in six weeks as a 50 mg tablet to be administered twice daily. RPR will hold a news conference on...